CyFlow CD13 PE-DyLight 594
品番 | BM509936 | ||
---|---|---|---|
抗体名 | Anti-Hu CD13 PE-DYLGT 594,WM15 | ||
包装単位 | 100 tests | ||
濃度 | - | ||
容量 | 0.4 ml | ||
関連製品 (アイソタイプコントロール) |
Mouse IgG1 PE-DyLight™ 594 (AU555075) |
||
反応性|交差吸着 | Human | Non-Human Primates | レーザー | Blue, Green, Yellow |
抗原 | CD13, APN, gp150 | 最大蛍光波長 | 618 nm |
クローン | WM15 | 最大励起波長 | 593 nm |
ホスト | Mouse | 標識/Format | PE-DyLight™ 594 |
アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD13 PE-DYLGT 594,WM15
特異性
The mouse monoclonal antibody WM15 recognizes the human CD13 cell surface glycoprotein, a 150 kDa molecule expressed on granulocytes, endothelial cells, epithelial cells and myeloid progenitors.
抗原情報
CD13 (APN; aminopeptidase N) is a 150 kDa type II transmembrane zinc-binding ectopeptidase expressed on various cell types. This metalloprotease preferentially catalyzes removal of neutral amino acids from small peptides, thus activating or inactivating bioactive peptides. CD13 has also role in extracellular matrix degradation, antigen processing and signal transduction, is important in inflammatory responses, regulates intercellular contact, cell motility and vascularization. CD13 is involved in protection of leukemic cells against apoptosis and its expression associated with poor prognosis of carcinomas.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Berndt MC, Musgrove E: Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells. Pathology. 1985·Jul; 17(3):392‑9. <·PMID:·3865147·>
• Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Musgrove E: Myeloid progenitor surface antigen identified by monoclonal antibody. Br·J·Haematol. 1985·Sep; 61(1):44136. <·PMID:·4052321·>
• Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·>
• Favaloro EJ, Browning T, Facey D: CD13 (GP150: aminopeptidase‑N): predominant functional activity in blood is localized to plasma and is not cell‑surface associated. Exp·Hematol. 1993·Dec; 21(13):1695‑701. <·PMID:·7902291·>
• McCormack E, Mujić M, Osdal T, Bruserud Ø , Gjertsen BT: Multiplexed mAbs: a new strategy in preclinical time‑domain imaging of acute myeloid leukemia. Blood. 2013·Feb·14; 121(7):e34‑42. <·PMID:·23243270·>
• Petrovic N, Schacke W, Gahagan JR, O'Conor CA, Winnicka B, Conway RE, Mina-Osorio P, Shapiro LH: CD13/APN regulates endothelial invasion and filopodia formation. Blood. 2007·Jul·1; 110(1):142‑50. <·PMID:·17363739·>
• Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F: Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC·Cancer. 2007·Jul·27; 7:140. <·PMID:·17655775·>
• Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M: Clinical significance of aminopeptidase N in non‑small cell lung cancer. Clin·Cancer·Res. 2006·Jul·1; 12(13):3971‑8. <·PMID:·16818694·>
• McMichael AJ, Beverley PCL, Cobbold S, et al (Eds): Leucocyte Typing III, White Cell Differentiation Antigens. Oxford·University·Press,·Oxford. 1987; 1‑1050. <·NLM·ID:·8913266·>
• Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford·University·Press,·Oxford. 1989; 1‑1820. <·NLM·ID:·8914679·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN